GENE ONLINE|News &
Opinion
Blog

Keytruda
Merck’s Keytruda Falls Short In Two Trials
2023-03-01
Antengene To Pair CD73 Inhibitor With Merck’s Keytruda In Clinical Collaboration
2022-12-27
Moderna Gets $250 Million from MSD in Personal Cancer Vaccine Licensing Option
2022-10-12
Merck Presents Positive News For Keytruda Combination in NSCLC
2022-09-13
Merck Reportedly Interested in Potential $40 Billion SeaGen Buyout
2022-07-08
How Did the Russian Invasion of Ukraine Affect Global Biopharma?
2022-03-16
Merck Breaks Off Keytruda Combo Trial with AstraZeneca, Begins Another with Imugene
2022-03-16
Recent Advances in Breast Cancer Treatments: An Overview
2022-01-15
Merck’s Keytruda Bags FDA Approval for Early Kidney Cancer in Adjuvant Setting
2021-11-18
Merck’s Keytruda Shows Survival Benefit as Adjuvant Therapy in Stage II Melanoma
2021-08-09
Day 3 ASCO 2021 Roundup: Lynparza, Keytruda and Novartis’ Radioligand Therapy Take Honors in Plenary Session
2021-06-09
Merck’s Anti-PD1 Therapy Receives Second FDA Approval for Esophageal Carcinoma
2021-03-25
Merck Acts on its Post-Keytruda Plan, Spends $1.85B to Acquire Pandion for Autoimmune Therapies
2021-02-26
Libtayo’s Second Approval in One Month Sets Up Lung Cancer Duel with Merck’s Keytruda
2021-02-24
Merck, Eisai’s Combo Therapy Registers Superiority against Pfizer’s Drug in Kidney Cancer Trial
2020-11-15
1 2 3
LATEST
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Scroll to Top